Please login to the form below

Not currently logged in
Email:
Password:

PharmaLex Group strengthens development consulting team

Carolyn Belcher and Lutz Wevelsiep join the German pharma services provider

PharmaLex Carolyn BelcherFriedrichsdorf, Germany-based PharmaLex Group has bolstered its development consulting division with the appointments of Carolyn Belcher and Lutz Wevelsiep.

Belcher (pictured right) joins PharmaLex as executive vice president of development consulting and scientific affairs, bringing over 14 years of regulatory affairs and strategic drug development leadership.

Most recently, Belcher served as head of global regulatory affairs at ICON, having been promoted from vice president in 2014.

She also brings experience from contract research organisation SRA International, where she was senior director and global head of regulatory affairs, and Constella Group, where she was head of strategic drug development services.

PharmaLex Lutz WevelsiepMeanwhile, Wevelsiep (pictured left) becomes senior director and principal consultant for development consulting and scientific affairs at PharmaLex, bringing over 25 years of EU and US regulatory affairs expertise.

He has spent the last 16 years of his career as head of global regulatory affairs at Basilea Pharmaceutica, based in Basel, Switzerland, and previously served as group leader for international regulatory affairs at Biogen.

Prior to this, Wevelsiep held a series of increasingly senior regulatory affairs and quality assurance roles at Roche both in Switzerland and the US.

Dr Thomas Dobmeyer, co-chief executive at PharmaLex, said: “It is important that we continue to strengthen our team and both Carolyn and Lutz come to us with a wealth of experience.”

Co-chief executive Dr Tilo Netzer added: “We are in a highly competitive market and having the ability to enhance our service lines with specialists who are at the top of their industry is a key attraction for our clients.”

1st February 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics